Background The comparative clinical utility of the disease-modifying treatments for mild
cognitive impairment and Alzheimer's disease that are approved or under review by the …

Biomarkers have been instrumental in population selection and disease monitoring in
clinical trials of recently FDA-approved drugs targeting amyloid-β to slow the progression of …

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that comprises
amyloid-beta protein (Aβ) as a main component of neuritic plaques. Its deposition is …

Amyloid-β (Aβ) peptide aggregation in the brain is a key factor in Alzheimer's disease.
However, direct inhibition of β-secretase or γ-secretase proves ineffective in reducing Aβ …

Rectifying the aberrant microenvironment of a disease through maintenance of redox
homeostasis has emerged as a promising perspective with significant therapeutic potential …

Disease-modifying therapies (DMT) for Alzheimer's disease (AD) are highly longed-for. In
this quest, anti-amyloid therapies take center stage supported by genetic facts that highlight …

Abstract Mild Behavioral Impairment (MBI) leverages later-life emergent and persistent
neuropsychiatric symptoms (NPS) to identify a high-risk group for incident dementia …

The tau protein undergoes pathological changes in Alzheimer's disease and other
tauopathies that eventually lead to functional impairments. Over the years, several …

Background Aging, a complex and profound journey, leads us through a labyrinth of
physiological and pathological transformations, rendering us increasingly susceptible to …

Alzheimer's disease (AD) poses a significant health challenge worldwide, and the
development of effective treatments necessitates a comprehensive understanding of its …